Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 4/2011

01.04.2011 | Editorial

Levosimendan: from coronary care to intensive care?

verfasst von: Karen Stuart-Smith

Erschienen in: Intensive Care Medicine | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Excerpt

Numerous multi-centre clinical trials have demonstrated that levosimendan is an effective agent in the management of decompensated heart failure [1]. It has a novel pharmacological profile which makes it particularly suited to improving the performance of the decompensated heart [2]. In the myofilament, levosimendan enhances the sensitivity of troponin C to calcium and stabilizes the Ca2+-troponin C complex [3]. The rate of formation of myosin actin cross bridges is increased, although the rate of dissociation of cross bridges is unaltered, so that there is a greater rate of force development during systole, while diastole is not impaired [4, 5]. Increased contractility is not accompanied by increased cellular metabolism, so that myocardial oxygen consumption is not elevated [1, 3]. There is no effect on heart rate. The inotropic properties of levosimendan are not compromised in the acidotic or hypoxic heart [3]. …
Literatur
1.
Follath F (2009) Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Dev Ther 3:73–78CrossRef
2.
Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G (2010) Intravenous levosimendan versus dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 12:404–410CrossRefPubMed
3.
4.
Haikala H, Linden IB (1995) Mechanism of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1):10–19
5.
Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM (2008) Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 294:H238–H248CrossRefPubMed
6.
Segreti JA, Marsh KC, Polakowski JS, Fryer RM (2008) Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1, 4, 5, 6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4, 5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J Pharmacol Exp Ther 325:331–340CrossRefPubMed
7.
du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A (2008) A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea-pig heart. Br J Pharmacol 154:41–50CrossRefPubMed
8.
Grossini E, Molinari C, Caimmi PP (2009) Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel. Br J Pharmacol 156:250–261CrossRefPubMed
9.
Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, Singer M (2009) Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 102:198–204CrossRefPubMed
10.
Pinto BB, Rehberg S, Ertmer C, Westphal M (2008) Role of levosimendan in sepsis and septic shock. Curr Opin Anaesth 21:168–177CrossRef
11.
De Kock I, Van Daele C, Poelaert J (2010) Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy. Acta Clin Belg 65:323–329PubMed
12.
De Becker D, Bracht H (2009) Levosimendan in early sepsis: when good ideas give poor results. Anesth Analg 109:1367–1369CrossRef
13.
Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietropaoli P (2005) Effect of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644CrossRefPubMed
14.
Cunha-Goncalves D, Perez-de-Sa V, Grins E, Dahm PL, Thörne J, Blomquist S (2009) Inotropic support during experimental endotoxemic shock: part I. The effects of levosimendan on splanchnic perfusion. Anesth Analg 109:1568–1575CrossRefPubMed
15.
Cunha-Goncalves D, Perez-de-Sa V, Larsson A, Thörne J, Blomquist S (2009) Inotropic support during experimental endotoxemic shock: part II. A comparison of levosimendan with dobutamine. Anesth Analg 109:1576–1583CrossRefPubMed
16.
Rehberg S, Ertmer C, Vincent JL, Spiegel HU, Köhler G, Erren M, Lange M, Morelli A, Seisel J, Su F, Van Aken H, Traber DL, Westphal M (2010) Effects of combined arginine vasopressin and levosimendan on organ function on ovine septic shock. Crit Care Med 38:2016–2023PubMed
17.
Schwarte LA, Schwartges I, Thomas K, Schober P, Picker O (2011) The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia. Intensive Care Med. doi:10.​1007/​s00134-011-2144-1 PubMed
18.
Yildiz O (2007) Vasodilating mechanisms of levosimendan: involvement of K+-channels. J Pharmacol Sci 104:1–5CrossRefPubMed
Metadaten
Titel
Levosimendan: from coronary care to intensive care?
verfasst von
Karen Stuart-Smith
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 4/2011
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-011-2204-6

Weitere Artikel der Ausgabe 4/2011

Intensive Care Medicine 4/2011 Zur Ausgabe

Correspondence

Accuracy of waste blood measurement in critically ill patients

Original

Non-pulmonary factors strongly influence the stress index

Editorial

Stress index in presence of pleural effusion: does it have any meaning?

Experimental

Mechanical influences on fluid leakage past the tracheal tube cuff in a benchtop model

Original

Multi-site and multi-depth near-infrared spectroscopy in a model of simulated (central) hypovolemia: lower body negative pressure

Original

Attitudes towards ethical problems in critical care medicine: the Chinese perspective

Neu im Fachgebiet AINS

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

11.04.2024 | Rückenschmerzen | Nachrichten

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren